UA118540C2 - Пристрої для трансмукозальної доставки ліків для застосування у полегшенні хронічного болю - Google Patents

Пристрої для трансмукозальної доставки ліків для застосування у полегшенні хронічного болю

Info

Publication number
UA118540C2
UA118540C2 UAA201406826A UAA201406826A UA118540C2 UA 118540 C2 UA118540 C2 UA 118540C2 UA A201406826 A UAA201406826 A UA A201406826A UA A201406826 A UAA201406826 A UA A201406826A UA 118540 C2 UA118540 C2 UA 118540C2
Authority
UA
Ukraine
Prior art keywords
chronic pain
drug delivery
transmucosal drug
delivery devices
pain relief
Prior art date
Application number
UAA201406826A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ендрю Фінн
Нірадж Васішт
Original Assignee
Біоделівері Сайєнсиз Інтернешнл, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Біоделівері Сайєнсиз Інтернешнл, Інк. filed Critical Біоделівері Сайєнсиз Інтернешнл, Інк.
Publication of UA118540C2 publication Critical patent/UA118540C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UAA201406826A 2011-12-21 2012-12-21 Пристрої для трансмукозальної доставки ліків для застосування у полегшенні хронічного болю UA118540C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578755P 2011-12-21 2011-12-21
PCT/US2012/071330 WO2013096811A2 (en) 2011-12-21 2012-12-21 Transmucosal drug delivery devices for use in chronic pain relief

Publications (1)

Publication Number Publication Date
UA118540C2 true UA118540C2 (uk) 2019-02-11

Family

ID=48669710

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201406826A UA118540C2 (uk) 2011-12-21 2012-12-21 Пристрої для трансмукозальної доставки ліків для застосування у полегшенні хронічного болю

Country Status (16)

Country Link
EP (1) EP2793870A4 (es)
JP (1) JP6255349B2 (es)
KR (4) KR20210003313A (es)
CN (2) CN104125828A (es)
AU (4) AU2012358308A1 (es)
BR (1) BR112014015329A2 (es)
CA (1) CA2859859A1 (es)
EA (2) EA201992762A1 (es)
HK (1) HK1203365A1 (es)
IL (2) IL233075A0 (es)
IN (1) IN2014DN06117A (es)
MX (2) MX362217B (es)
SG (3) SG11201403075XA (es)
UA (1) UA118540C2 (es)
WO (1) WO2013096811A2 (es)
ZA (1) ZA201804381B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163529A2 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
AU776904B2 (en) 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2002088157A1 (fr) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. Derives pyrazolyl-o-glycoside n-substitues et medicament contre le diabete en contenant
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
WO2007070632A2 (en) * 2005-12-13 2007-06-21 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
AU2007238092A1 (en) 2006-04-12 2007-10-25 Spinalmotion, Inc. Posterior spinal device and method
AU2007275581B2 (en) * 2006-07-21 2011-09-08 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
EP1897543A1 (en) * 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
GB0620661D0 (en) * 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
CN102056578A (zh) * 2008-06-23 2011-05-11 生物递送科学国际公司 多向粘膜给药装置及使用方法
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Also Published As

Publication number Publication date
MX2014007350A (es) 2014-09-15
SG11201403075XA (en) 2014-07-30
AU2021202042A1 (en) 2021-04-29
EP2793870A4 (en) 2016-02-17
SG10202012743WA (en) 2021-01-28
CA2859859A1 (en) 2013-06-27
EA201491046A1 (ru) 2014-11-28
IN2014DN06117A (es) 2015-08-14
WO2013096811A3 (en) 2014-07-24
KR20140106720A (ko) 2014-09-03
SG10201710667YA (en) 2018-02-27
BR112014015329A8 (pt) 2017-06-13
KR20210003313A (ko) 2021-01-11
AU2019202602A1 (en) 2019-05-02
CN104125828A (zh) 2014-10-29
HK1203365A1 (en) 2015-10-30
IL285091A (en) 2021-08-31
MX2021012154A (es) 2021-11-03
ZA201804381B (en) 2022-12-21
KR20190110628A (ko) 2019-09-30
AU2017258916A1 (en) 2017-11-30
IL233075A0 (en) 2014-07-31
AU2017258916B2 (en) 2019-01-17
KR102026321B1 (ko) 2019-09-27
BR112014015329A2 (pt) 2017-06-13
MX362217B (es) 2019-01-09
WO2013096811A2 (en) 2013-06-27
EP2793870A2 (en) 2014-10-29
JP2015500886A (ja) 2015-01-08
EA201992762A1 (ru) 2020-07-31
JP6255349B2 (ja) 2017-12-27
CN110123792A (zh) 2019-08-16
KR20220047889A (ko) 2022-04-19
AU2012358308A1 (en) 2014-07-24
EA034529B1 (ru) 2020-02-18

Similar Documents

Publication Publication Date Title
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
MY163517A (en) Improved device and method for delivery of a medicament
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
AU2011328009A8 (en) Compounds and methods for treating pain
MX340290B (es) Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación.
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2011100769A3 (en) Kinase modulators for the treatment of cancer
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX2021012154A (es) Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico.
CL2012000488A1 (es) Uso de carbon vegetal para tratar una sobredosis de etexilato de dabigatran.
EA201590760A1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
UA86338U (ru) Способ лечения беременных с гестационным диабетом
AU2014900743A0 (en) A method to deliver pain relief with a reduced risk of overdose, using 1:1, 2:1, 3:1 and 4:1 mixtures of naloxone and fentanyl for nasal administration.
NZ724912A (en) Transmucosal drug delivery devices for use in chronic pain relief
UA67427U (ru) Способ лечения фиброзно-кавернозных форм органного туберкулеза
UA33217U (ru) Способ лечения больных хроническими дерматозами